Patients with severe liver diseases usually have a lower concentration of albumin (28), which plays an important role in the clinical evaluation of liver function and is used as a diagnostic biomarker in the management of NAFLD (29). The gene discussed is ALB; the disease is metabolic dysfunction-associated steatotic liver disease.